In previous studies, IL-6R antagonists were mainly used for the treatment of autoimmune diseases [30–32], but recently, IL-6R-targeting inhibitors were also found to be effective in the treatment of severe and critical COVID-19 [33]. Here, IL6R is linked to autoimmune disease.